biostudies-literatureKrakow EFNCI NIH HHS1069-1082https://www.ebi.ac.uk/biostudies/studies/S-EPMC11406181biostudies-literatureUnknown144(10)<h4>Abstract</h4>Relapse is the leading cause of death after allogeneic hematopoietic stem cell transplantation (HCT) for leukemia. T cells engineered by gene transfer to express T cell receptors (TCR; TCR-T) specific for hematopoietic-restricted minor histocompatibility (H) antigens may provide a potent selective antileukemic effect post-HCT. We conducted a phase 1 clinical trial using a novel TCR-T product targeting the minor H antigen, HA-1, to treat or consolidate treatment of persistent or recurrent leukemia and myeloid neoplasms. The primary objective was to evaluate the feasibility and safety of administration of HA-1 TCR-T after HCT. CD8+ and CD4+ T cells expressing the HA-1 TCR and a CD8 coreceptor were successfully manufactured from HA-1-disparate HCT donors. One or more infusionBloodHA-1-targeted T-cell receptor T-cell therapy for recurrent leukemia after hematopoietic stem cell transplantation.PMC11406181P30 CA015704K23 CA154532Summers CKanaan SBBlack RGChapuis AGGreenberg PDCunningham TMBleakley MDenker AEBiernacki MAGooley TAYeh ACVartanian NFurlan SNYeung CCSBrault MRiddell SRTill BGMaloney DGBar MKrakow EFDahlberg ACassaday RDWoodward KBDossa RGNewell EWfalseHA-1-targeted T-cell receptor T-cell therapy for recurrent leukemia after hematopoietic stem cell transplantation.<h4>Abstract</h4>Relapse is the leading cause of death after allogeneic hematopoietic stem cell transplantation (HCT) for leukemia. T cells engineered by gene transfer to express T cell receptors (TCR; TCR-T) specific for hematopoietic-restricted minor histocompatibility (H) antigens may provide a potent selective antileukemic effect post-HCT. We conducted a phase 1 clinical trial using a novel TCR-T product targeting the minor H antigen, HA-1, to treat or consolidate treatment of persistent or recurrent leukemia and myeloid neoplasms. The primary objective was to evaluate the feasibility and safety of administration of HA-1 TCR-T after HCT. CD8+ and CD4+ T cells expressing the HA-1 TCR and a CD8 coreceptor were successfully manufactured from HA-1-disparate HCT donors. One or more infusion2024-01-01T00:00:00Z2024 Sep2026-05-29T19:46:38.973Z2026-04-08T05:51:04.252ZS-EPMC114061813868396610.1182/blood.2024024105